Immunotherapies are a broad class of agents that generally work by activating the immune system to destroy cancerous cells. In bladder cancer, these include monoclonal antibody treatments, antibody-drug conjugates, and live-attenuated bacterial infusions. Monoclonal antibody treatments such as avelumab, ...
Utilizing a Multidisciplinary Team Approach to Bladder Cancer Treatment AEs to Monitor With Enfortumab Vedotin/Pembrolizumab in Advanced Bladder Cancer Nivolumab/Chemo Approval Adds Options for Urothelial Carcinoma, Expert Says Expert Discusses Strategies for Managing BCG Shortage in Bladder Cancer ...
One treatment, bacillus Calmette-Guerin (BCG) therapy, sends in helpful bacteria through a catheter directly to your bladder that trigger the immune system. BCG is used for cancers that haven't spread. Another type of therapy, immune checkpoint inhibitors, targets certain proteins on cancer cells...
Radiation therapyinvolves the use of high-energy beams targeted at your tumor to destroy the cancerous cells. For bladder cancer, radiation therapy is delivered from a machine that goes around your body, directing the energy beams to precise regions of your body. This can be used after the su...
This suggests that conventional treatments have a limited role in inhibiting the progression of bladder cancer. As a result, novel diagnostic strategies and treatment options are being explored. Significant advancements in the design and use of nanotechnology for the treatment of cancer have been done...
BCGCystectomyRadiotherapyChemotherapyPurpose: To review the standards and new developments in diagnosis and management of high-risk T1 bladder cancer with emphasis on the role of radiotherapy (RT) and radiochemotherapy (RCT). Material and Methods: A systematic review of the literature on developments ...
Thomas Flaig, MD, discusses recent updates seen in the bladder cancer space and how they have led to changes to the NCCN guidelines.
In a single center, placebo controlled, double blinded Phase I/II interventional clinical trial of non-muscle invasive bladder cancer, all primary end points of safety and efficacy of alpha1-oleate treatment are reached, as evaluated in an interim analysis. Intra-vesical instillations of alpha1-...
In your experience, what are the primary factors driving the use of intravesical gemcitabine for high-risk NMIBC vs other options? With BCG, which is the gold standard of treatment for high-risk non-muscle invasive bladder cancer, unfortunately, we have had shortages in the United States and ...
cancer (Matsuzaki and Chin, 2000). Based on these findings, study bySeow et al. (2010)set to investigate how conventional bladder cancer treatment by Bacillus Calmette-Guerin (BCG) immunotherapy compares with live and lyophilisedLactobacillus rhamnosus GG(LGG) treatment of bladder t...